That's good news, then. I'll look forward to seeing Ratain at ASCO and seeing what he has to say about the development. I admit that still seems high to me, but the data are the data.
I would expect success rates in Phase III to start rising by mid-10s as a result.
Next up, smoother approval path and more sponsor acceptance for trials with target screening.
News 
Market Data 
Discover 
